stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) P/S ratio
As of 6 November 2026, Sarepta Therapeutics, Inc. (SRPT) trades at a P/S ratio of 1.0×. Over the past ten years it has ranged from 0.5× (July 2025) to 308× (October 2016); the current reading is higher than 8% of that period. That is below the Biotechnology industry median of 9.4× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 1.0× | (83.87%) |
| FY2024 | 6.1× | (14.99%) |
| FY2023 | 7.1× | (38.97%) |
| FY2022 | 11.7× | 12.37% |
| FY2021 | 10.4× | (57.63%) |
| FY2020 | 24.6× | (1.35%) |
| FY2019 | 24.9× | 3.86% |
| FY2018 | 24.0× | 8.36% |
| FY2017 | 22.2× | (84.09%) |
| FY2016 | 139× | (16.67%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 1.0× | 2.81% |
| Jun 2026 | 1.0× | (8.25%) |
| Mar 2026 | 1.0× | 6.71% |
| Dec 2025 | 1.0× | 22.48% |
| 35 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. | 1.0× |
| HRMY Harmony Biosciences Holdings, Inc. compare | 2.0× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 5.3× |
| VIR Vir Biotechnology, Inc. compare | 6.8× |
| MESO Mesoblast Limited compare | 148× |
| Biotechnology industry median | 9.4× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)